Literature DB >> 16223671

Aortic allograft vasculopathy is mediated by CD8(+) T cells in Cyclosporin A immunosuppressed mice.

Ellen L Vessie1, Gregory M Hirsch, Timothy D G Lee.   

Abstract

We investigated the role of CD4(+) T cells and CD8(+) T cells in mediating allograft vasculopathy in Cyclosporin A (CyA) immunosuppressed mice. We first established that a dose of 50 mg/kg/d CyA was required to prevent acute rejection in C57BL/6 mice. CyA given at 50 mg/kg/d did not prevent allograft vasculopathy in either cardiac or aortic transplants in these mice. Using CD4(-/-) and CD8(-/-) mice, we established that CyA immunosuppression at this dose was only effective at preventing allograft vasculopathy in mice lacking CD8(+) T cells. This implicates CD8(+) T cells in the development of AV in situations of clinical cardiac transplantation where CyA is still the mainstay of immunosuppressive therapy. We confirmed the important role for CD8(+) T cells in AV in the face of CyA immunosuppression by allopriming mice in the presence of CyA and transferring alloprimed T cells into RAG1(-/-) immunodeficient mice. The RAG1(-/-) mice were also treated with CyA. In this situation (CyA present during the allopriming and in the recipient), only primed CD8(+) T cells could mediate AV, primed CD4(+) T cells could not. Alloprimed CD8(+) T cells raised in the presence of CyA exhibited markedly reduced direct recognition responses (as measured by MLR) and effector responses (as measured by cytotoxic activity). In contrast indirect activation was retained. We interpret these data to suggest that in the face of CyA immunosuppression CD4(+) T cell effector function is ablated while CD8(+) T cell function remains partially intact. The in vitro data suggest that the indirect pathway remains intact in this population of CyA resistant CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223671     DOI: 10.1016/j.trim.2005.02.006

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  7 in total

Review 1.  Mechanism of arterial remodeling in chronic allograft vasculopathy.

Authors:  Qichang Zheng; Shanglong Liu; Zifang Song
Journal:  Front Med       Date:  2011-10-02       Impact factor: 4.592

Review 2.  Safety assessment of probiotics for human use.

Authors:  Mary Ellen Sanders; Louis M A Akkermans; Dirk Haller; Cathy Hammerman; James Heimbach; Gabriele Hörmannsperger; Geert Huys; Dan D Levy; Femke Lutgendorff; David Mack; Phoukham Phothirath; Gloria Solano-Aguilar; Elaine Vaughan
Journal:  Gut Microbes       Date:  2010-03-04

3.  Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment.

Authors:  J Kwun; B C Oh; A C Gibby; R Ruhil; V T Lu; D W Kim; E K Page; O P Bulut; M Q Song; A B Farris; A D Kirk; S J Knechtle; N N Iwakoshi
Journal:  Am J Transplant       Date:  2012-07-03       Impact factor: 8.086

4.  Neutrophil mediated smooth muscle cell loss precedes allograft vasculopathy.

Authors:  Chelsey L King; Jennifer J Devitt; Timothy D G Lee; Camille L Hancock Friesen
Journal:  J Cardiothorac Surg       Date:  2010-06-22       Impact factor: 1.637

5.  A Class II-Restricted CD8γ13 T-Cell Clone Protects During Chlamydia muridarum Genital Tract Infection.

Authors:  Raymond M Johnson; Norma Olivares-Strank; Gang Peng
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

6.  Early innate immune events induced by prolonged cold ischemia exacerbate allograft vasculopathy.

Authors:  Jennifer J Devitt; Chelsey L King; Timothy D G Lee; Camille L Hancock Friesen
Journal:  J Cardiothorac Surg       Date:  2011-01-06       Impact factor: 1.637

7.  Chronic rejection pathology after orthotopic lung transplantation in mice: the development of a murine BOS model and its drawbacks.

Authors:  Stéphanie De Vleeschauwer; Wolfgang Jungraithmayr; Shana Wauters; Stijn Willems; Manuela Rinaldi; Annemie Vaneylen; Stijn Verleden; Anna Willems-Widyastuti; Ken Bracke; Guy Brusselle; Erik Verbeken; Dirk Van Raemdonck; Geert Verleden; Bart Vanaudenaerde
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.